This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Nature Reviews Cardiology, Published online: 26 June 2024; doi:10.1038/s41569-024-01046-6 In this Review, Khan and colleagues explore the evolving global epidemiology of heart failure (HF), focusing on changes in incidence and prevalence across the spectrum of left ventricular ejection fraction. The authors highlight the disparities in our understanding of HF epidemiology in low-income and middle-income countries, affirming the need for improved surveillance and resource allocation in vulnerable
Lower extremity peripheral artery disease (PAD) often results from atherosclerosis, and is highly prevalent in patients with type 2 diabetes mellitus (T2DM). Individuals with T2DM exhibit a more severe manifes.
(MedPage Today) -- People showed lingering long-term effects of childhood cardiovascular risk factors no matter the changes in adulthood, a population-level cohort study found. Various childhood risk factors were associated with adult cardiovascular.
Pocket-Sized Kardia 12L ECG System milla1cf Tue, 06/25/2024 - 18:55 June 25, 2024 — AliveCor , the global leader in AI -powered cardiology, today announced the U.S. Food and Drug Administration ( FDA ) clearance and commercial launch of KAI 12L AI technology and the Kardia 12L ECG System. This is the world’s first AI that can detect life-threatening cardiac conditions, including heart attacks, using a reduced leadset.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
(MedPage Today) -- ORLANDO -- Earlier screening and treatment for gestational diabetes, as well as a "shift to a holistic life-course approach," are needed to reduce the toll it takes on women. That was the conclusion of a series of papers published.
Even though there is substantial variability in the contents and nutritional profiles of plant-based meat alternatives (PBMAs), the nutritional profiles tend to reflect a heart-healthy dietary pattern. A review article of the available studies directly comparing the impact of plant-based and animal-based meats consistently suggests that the plant-based alternatives improve cardiovascular risk factors.
25 June 2024 In the case against the Mail on Sunday (Associated Newspapers) and Barney Calman, Health Editor of the Mail on Sunday. I have written nothing on this blog for a while, because of my on-going legal case. Now we have a judgment, part one. Step backwards for a moment. Zoë Harcombe and I are suing the Mail on Sunday and Barney Calman for libel.
This prespecified analysis of the POST-PCI randomized clinical trial analyzes clinical outcomes in patients with vs without acute coronary syndrome (ACS) who have undergone high-risk percutaneous coronary intervention (PCI) according to a follow-up strategy of routine surveillance stress testing vs standard care.
(MedPage Today) -- ORLANDO -- A surprisingly high prevalence of hypercortisolism was found in people with uncontrolled diabetes, according to the two-part, phase IV CATALYST study. Of 1,055 patients with difficult-to-treat type 2 diabetes, 24.
milla1cf Tue, 06/25/2024 - 18:58 June 25, 2024 — Nano-X Imaging (Nanox), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography ( SCCT ), being held July 18-21 in Washington, D.C.
The healthcare field is facing a deluge of potential artificial intelligence products, and Durham, N.C.-based Duke Health has opened an AI testing lab to determine which products are the most effective for heart care.
milla1cf Tue, 06/25/2024 - 18:52 June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the first location in the United States to install GE HealthCare ’s latest Allia Image Guided System (IGS) Pulse, which was designed to provide exceptional image quality and improve workflow for the diagnosis and treatment of cardiovascular diseases ( CVD ).
(MedPage Today) -- ORLANDO -- Adding a low dose of an SGLT2 inhibitor to insulin improved renal function and glycemic control in adolescents with type 1 diabetes (T1D), the late-breaking ATTEMPT trial found. In the 98-patient study, treatment.
(MedPage Today) -- When patients are expecting a baby, they hope nothing goes wrong. But at least one in 20 people who are pregnant develop preeclampsia, a high blood pressure disorder that kills 70,000 women and 500,000 babies worldwide every.
Vutrisiran, a new drug made by Alnylam Pharmaceuticals to treat ATTR amyloidosis with cardiomyopathy, reduced the risk of death by 36% in patients, the drugmaker announced June 24.
Do autoimmune diseases independently correlate with coronary atherosclerosis and atherosclerotic cardiovascular disease (ASCVD) risk, and do traditional cardiovascular risk factors modulate the risk?
Despite 2019 recommendations from the American College of Cardiology and the American Heart Association warning adults against routinely taking aspirin for heart health, many are still doing so , according to a new study from Cleveland Clinic researchers.
Palpitations are a common reason for athletes to seek medical care. Although often benign, palpitations may serve as a harbinger for underling cardiac pathology. Given the unique challenges in this population, this review will serve to discuss the basic underlying pathophysiology, which may predispose athletes to palpitations. In addition, we will review the aetiologies, diagnostic evaluation, management and counselling strategies for some of the most common diagnoses seen in athletes.
The FDA accepted the NDA for olezarsen, an RNA-targeted medicine, in familial chylomicronemia syndrome for priority review, with a PDUFA date set for December 19, 2024.
This study compared the prognostic value of quantified thoracic artery calcium (TAC) including aortic arch on chest CT and coronary artery calcium (CAC) score on ECG-gated cardiac CT. Methods A total of 2412 participants who underwent both chest CT and ECG-gated cardiac CT at the same period were included in the Multi-Ethnic Study of Atherosclerosis Exam 5.
FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.
Background We aimed to investigate the effectiveness of fixed-dose combination therapy (polypill) for primary and secondary prevention of major cardiovascular diseases in a typical rural setting. Methods The PolyPars Study is a two-arm pragmatic cluster-randomised trial nested within the PARS cohort study, including all residents aged over 50 years in the entire district in southern Iran.
Clinical introduction Vignette A woman in her 50s, with a history of atrial fibrillation, was admitted for a coronary angiography (CA) due to dyspnoea on exertion with a reduced ejection fraction of 40%. CA was performed after 24 hours interruption of apixaban and demonstrated normal coronary arteries. The patient was discharged and apixaban was restarted 10 hours later.
It is estimated that by 2050, 17% of the world’s population will be greater than 85 years old, which, combined with cardiovascular disease (CVD) being the leading cause of death and disability, sets an unprecedented burden on our health and care systems. This perfect storm will be accompanied by a rise in the prevalence of CVD due to increased survival of patients with pre-existing CVD and the incidence of CVD that is associated with the process of ageing.
The latest in our series of quizzes on the ESC/EAS 2019 Dyslipidemia guidelines tests your knowledge on pharmacotherapy recommendations from the document!
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death around the world. Consequently, the identification of asymptomatic patients at high risk of ASCVD events is vital to ensure the timely initiation of primary prevention therapies. Traditional clinical risk factor-based models are currently recommended for initial risk stratification in patients at low risk or without ASCVD. 1 These remain imperfect, with low sensitivity for detection of premature artery disease in you
Findings underscore the impact of socioeconomic factors on disease management and therapeutic outcomes in patients with rheumatoid arthritis from different socioeconomic classes.
Despite the existence of well-established risk factors and effective pharmacological treatments for major cardiovascular disease (CVD), these conditions remain among the leading causes of premature death and disability, exerting a substantial burden on health systems worldwide. Previous randomised studies have provided compelling evidence for the efficacy of blood pressure and lipid-lowering treatments in reducing the risk of CVD, suggesting unique opportunities for the prevention of this chroni
Phase 2 data presented at EULAR 2024 showed gout patients on febuxostat and ruzinurad were more likely to achieve the target serum uric acid level than those on febuxostat alone.
Cardiogenic shock is a common complication in patients who present with acute myocardial infarction (AMI) and is the leading cause of death in this population. Even with immediate revascularization, death rates remain high.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
140 
Let's personalize your content